Kornimate/medical-research-clean huggingface dataset:
lumbopelvic stabilization versus pilates exercises on gait phases and peak pressure on foot in low back pain

Conditions: Low Back Pain

Summary: the purpose of this trial is to investigate and compare between lumbopelvic stabilization and pilates exercises on gait cycle phases and maximum peak pressure on the foot in chronic nonspecific low back pain?

lbp is the leading cause of activity limitation, results in significant losses in productivity at work, and incurs billions of dollars in medical expenditure annually so, the aim of physical therapy treatment in the patient with chronic nonspecific low back pain is more effective in improving gait cycle phases and maximum peak pressure on the foot and help lbp patients to walk normally as much as possible, also this will improve our body of knowledge about the best modalities for treating lbp. the finding of this study may help lbp patients avoid exposure to complications due to altered gait cycle phases and maximum peak pressure on the foot. also, it will help physiotherapists to know which treatment will be effective in improving gait cycle phases and maximum peak pressure on the foot. one hundred patients with mechanical low back pain will be allocated randomly to three groups; group a will receive pilates, group b will receive lumbopelvic stabilization exercise and group c will receive strengthening exercises for the abdominals, back, and hip muscles

Eligibility criteria:
inclusion criteria: 1. their age between 20 and 40 years 2. patients is required to have chronic nonspecific lbp (more than12 weeks), deﬁned as pain in the lumbar and/or buttock region (defined as pain reported below the level of t12 and no lower than the buttock line). 3. patients will be excluded if they have signs of serious spinal pathology (red flags) including significant trauma, unexplained weight loss, and widespread neurologic changes exclusion criteria: 1. subjects with specific back pain (fracture, osteoporosis or degenerative changes, prolapse intervertebral disc, bone disorders, arthritis, tumour), 2. subjects with neurological involvement (radiculopathy, myelopathy), 3. subjects with previous spinal surgery

Keywords: lumbopelvaic stabilization exercise pilates exercise gait cycle phases peak pressure
video education: capitalizing on caregiver time spent in the pediatric emergency department waiting room

Conditions: Child Passenger Seat Safety

Summary: the purpose of this study is to determine if video education is an effective means of caregiver education in the waiting room of a pediatric emergency department (ed). this will be tested with the showing of a child passenger safety video.


Eligibility criteria:
inclusion criteria: * caregivers of patients presenting to children's hospital of wisconsin for treatment * family use of automobile for transportation exclusion criteria: * non-english speaking caregivers * triage level 1 or 2 or requiring immediate medical attention
impact of treatment with rituximab on the progression of humoral acute rejection after renal transplantation

Conditions: Humoral Rejection in Kidney Transplantation

Summary: assessing the impact of j12 curative treatment with rituximab (375 mg / m² on j5) based on a composite "treatment failure"


Eligibility criteria:
inclusion criteria: * patient adult male or female (age 18 years), kidney transplantation for less than one year (transplant from a living donor or deceased), with acute humoral rejection defined by : * the deterioration of renal function assessed by serum creatinine increase of more than 20% compared to the best value, or * in the first 28 days after transplantation, no significant creatinine decrease, and * at least 2 of the 3 following criteria: * tissue damage such as (a) acute tubular necrosis, (b) presence of monocytes or granulocytes in the cpt and / or glomeruli and / or capillary thrombosis, (c) intimal arteritis / fibrinoid necrosis * c4d level of cpt and / or presence of ig or complement in lesions of fibrinoid necrosis * presence of hla antibodies directed against the donor. patient having given his written consent to participate in the clinical trial. exclusion criteria: * pregnant or lactating * women during their reproductive years without effective contraception, * a patient with multiple organ transplants, * patients with clinically active infection by hcv uncontrolled * patients with active infection, or suspected of infection by hiv or hbv, and tuberculosis, * patients with heart failure class iv (nyha) cardiac disease or uncontrolled * patients for whom vaccination is scheduled, * patient with disabilities did not allow an understanding of the requirements of the test * patient in safeguarding justice, guardianship or trusteeship, * patient with cons-indication to rituximab (known hypersensitivity to any component or murine protein) * patient had previously received rituximab within 3 months before inclusion * patient participation in another clinical trial

Keywords: kidney transplantation acute humoral rejection rituximab
closed loop tes for enhancing slow wave sleep

Conditions: Sleep Disturbance; Insomnia

Summary: compare closed-loop with open-loop application of tes to enhance slow waves of sleep.

note: fda has determined that tes with the stimulus parameters as specified for this trial presents no significant risk, so that fda clearance is not required. several findings suggest that transcranial electrical stimulation (tes) may be particularly effective if it is aligned with ongoing brain activity. one condition of the present research is an open-loop design, in which tes pulses (0.75 hz pulses; 2.0 ma) are presented during slow wave sleep. the other condition is a closed-loop design, using identical pulses, but these will be phase aligned with the slow waves of sleep, measured by the electroencephalogram (eeg). the hypothesis is that closed-loop tes will be more effective in enhancing the amplitude and duration of slow wave sleep than open-loop tes.

Eligibility criteria:
inclusion criteria: * healthy adults exclusion criteria: * persons with epilepsy

Keywords: transcranial electrical stimulation
technique optimization with whole-body diffusion-weighted mri

Conditions: Healthy

Summary: whole body diffusion-weighted imaging is a functional magnetic resonance imaging technique that characterizes tissue by probing changes in water diffusion secondary to differences in the tissue microstructure. these changes in water diffusion result in differences in signal intensity on diffusion-weighted images that are quantified with the apparent diffusion coefficient (adc). in malignant lesions, the extravascular extracellular space (ees) will be diminished, due to the increased number of cells. this will restrict water diffusion, identified by increased signal intensity (si) on native diffusion-weighted images and low adc. contrary, in tissue with low cellularity, like benign lesions and treatment induced necrosis, the ees will be enlarged due to the lower density of cells, or in case of necrosis, the complete absence of cellular organization. this will facilitate water diffusion, leading to absent si on native diffusion-weighted images and high adc. the purpose of this study is to image anatomy and lymph nodes in healthy volunteers with whole body diffusion-weighted imaging. this way maps of normal anatomy can be created on the whole body diffusion-weighted images which can be used as a reference in further studies with patients scanned with the same whole body diffusion-weighted imaging scan protocol. a group of 30 healthy volunteers will receive a whole body diffusion-weighted imaging scan on a 3 tesla t-mri system. a total scan session will take about 30 minutes. contrast administration is not required and patients will not be exposed to radiation.


Eligibility criteria:
inclusion criteria: * healthy volunteers exclusion criteria: * no severe illness in the past * no current infection/inflammation
sanfu herbal patch and sanfu moxibustion for persistent allergic rhinitis: a controlled clinical trial

Conditions: Patch,Chinese Herb; Moxibustion; Allergic Rhinitis

Summary: to observe the efficacy of sanfu herbal patch and sanfu moxibustion on persistent allergic rhinitis,and comparing the differences between the combination of these 2 methods with each method alone.


Eligibility criteria:
inclusion criteria patients recruited to this study must meet the following inclusion criteria: 1. males or females aged between 5 and 60 years. 2. each par patient must be diagnosed by an otolaryngologist using the following diagnostic criteria: major symptoms of paroxysm rhinocnesmus, continuous sneezing, nasal obstruction, and significant quantities of clear and thin nasal mucus, accompanied by symptoms of hyposmia and itching of the eyes and throat. these symptoms should last for or add up to 1 hour a day. the attacks should occur for more than 4 weeks and at last for at least 4 days each week. 3. one of 2 laboratory results is positive: skin prick test or serum high circulating levels of allergen-specific ige antibody detected by a specific blood test for allergy called a radioallergosorbent (rast) test 4. the course of the disease is more than 1 year. 5. voluntary signing of an informed consent form. 6. no current participation in any other clinical trials. exclusion criteria patients with any of the following conditions will be excluded: 1. allergies to the herbal medicines, a moxa smoke or adhesive tape applied in this study, and the skin at the specific acupoint has physical scars or breakage. 2. patients with other allergic diseases, such as allergic asthma. 3. patients who received acupuncture and moxibustion treatment, chinese herbal medicine, nasal inhalation of herbal medicine, physical therapy or other external treatment for ar within the last 4 weeks 4. patients who received immune therapy or systematic hormonotherapy in the past 1 year. 5. pregnant women, lactating women, or women preparing for pregnancy in 2 years. 6. patients with serious medical disorders such as congenital heart disease, severe nephropathy, mental diseases, and infectious diseases including tuberculosis, hepatitis, and aids.
low dose primaquine for clearance of gametocytes

Conditions: Malaria; Asymptomatic Malaria; Plasmodium Falciparum

Summary: primaquine (pq) is currently the only available drug that can clear mature transmission stages of p. falciparum parasites. pq was previously shown to clear gametocytes that persist after artemisinin-combination therapy. however, there are safety concerns about the use of pq at the currently recommended dose of 0.75mg/kg in individuals who are glucose-6-phosphate dehydrogenase (g6pd) deficient. pq causes transient but significant haemolysis in g6pd deficient individuals; this side-effect is dose dependent. there are indications that a lower dosing of pq may effectively reduce gametocyte carriage but the lowest efficacious dose for gametocyte clearance is currently unknown. recently, the world health organization changed their recommendation to a low dose of primaquine, 0.25mg/kg. however, there is no direct evidence on the extent to which (low dose) pq prevents malaria transmission to mosquitoes and what the lowest efficacious dose is. in the current study we aim to identify the lowest efficacious dose of pq in individuals with normal g6pd function. children with asymptomatic malaria and normal g6pd enzyme function will be randomized to treatment with artemether-lumefantrine alone or in combination with low doses of pq. all enrolled individuals will receive a full three-day course of al, and will be randomized to receive a dose of primaquine or placebo with their fifth dose of al. efficacy will be determined based on gametocyte carriage during follow-up, measured by molecular methods. for a subset of participants with patent gametocytes, primaquine effect on infectivity to mosquitoes will be assessed by membrane feeding assays


Eligibility criteria:
inclusion criteria: 1. age \> 2 years and \<15 years 2. weight over 10kg 3. p. falciparum parasitaemia \>1,000 parasites and \<200,000 parasites/µl 4. p. falciparum gametocytes detected by microscopy 5. normal g6pd enzyme function 6. informed consent by legally acceptable representative exclusion criteria: 1. enrolled in another study 2. fever or history of fever in the last 24 hours 3. evidence of severe illness/ danger signs 4. known allergy to study medications 5. hb \< 8g/dl 6. started menstruation 7. pregnancy or breastfeeding 8. antimalarials taken within the last 2 days 9. primaquine taken within the last 4 weeks 10. blood transfusion within the last 90 days 11. non-falciparum malaria co-infection
measurement of the retinal oxygen saturaiton after long-term silicon oil tamponade

Conditions: Retinal Detachment

Summary: the purpose of this study is to evaluate the effects of long-term tamponade with silicone oil on retinal saturation with oxymap.

silicone oil is the first choice treatment for long-term vitreous replacement in complicated cases of retinal detachment. however, it will cause various problems for permanent tamponade, such as keratopathy, glaucoma, cataracts, and silicone oil emulsification3. in addition, silicone oil has the potential to cause retinal toxicity. moreover, the gravity and mechanical pressure of the silicone oil on the retina may influence retinal blood flow and, and the presence of silicone oil in the vitreous cavity may block the oxygen exchange between the retinal surface and the vitreous humor, resulting in the metabolic disturbance of the retina. in this study, the investigators utilized a noninvasive measurement (oxymap, reykjavik, iceland) to evaluate the effect of silicone oil tamponade on oxygen saturation and diameter in retinal vessels in complicated retinal detachment cases.

Eligibility criteria:
inclusion criteria: * initial silicone oil tamponade duration of more than 3 months * transparent reflecting media * intraocular pressure (iop) between 11 and 21mmhg * complete retinal re-attachment * healthy contralateral eye. exclusion criteria: * severe refractive media opacity (serious keratoleukoma and cataracts) * silicone oil emulsification * ocular hypertension * retinal detachment * retinal scar within the main vascular arch * any ocular disease and any history of surgery in the contralateral eye * any type of systemic disease * pregnancy

Keywords: silicone oil retinal saturation retinal blood flow retinal detachment
impact of neuropsychological evaluation on epilepsy treatment

Conditions: Epilepsy

Summary: the present study aims to expand the evidence base of neuropsychological services in the context of medical management of epilepsy, examining whether treatment outcome and patient satisfaction with medical care are significantly improved when neuropsychological evaluation is included as an additional component of medical care within a comprehensive epilepsy center. all participants will complete an initial survey and a follow-up survey regarding views towards their epilepsy treatment. participants will be randomized into one of two groups. one group will be given a neuropsychological battery in addition to the survey. the primary study hypothesis is that the addition of neuropsychological services to treatment-as-usual will result in significant improvements in (a) satisfaction with medical care, (b) patient perceived treatment outcome, and (c) physician-rated medical compliance. the secondary hypothesis is that participants who undergo neuropsychological evaluation will be generally satisfied with their experience with neuropsychological services.


Eligibility criteria:
inclusion criteria: * 18 years of age or older * experiencing some degree of epilepsy-related symptoms, but not of such severity as to preclude them from being able to provide consent or undergo neuropsychological assessment (requiring extended inpatient treatment, severely aphasic, or mmse score \< 25) exclusion criteria: * previously undergone neuropsychological testing * currently pursuing surgical treatment for epilepsy
iron in congestive heart failure

Conditions: Heart Failure; Iron Deficiency; Anemia

Summary: the hypothesis to be tested is whether treatment with intravenous iron (ferric carboxymaltose) will improve left-ventricular ejection fraction in patients with heart failure and iron deficiency as determined by cardiac magnetic resonance imaging.


Eligibility criteria:
inclusion criteria: * congestive heart failure * at least 18 years of age * iron deficiency * dyspnea class ii or iii according to new york heart association * left-ventricular ejection fraction ≤ 45% exclusion criteria: * known sensitivity to any of the products to be administered during dosing * immediate need of transfusion * patients presenting with an active infection * thalassaemia * other forms of microcytic anemia not caused by iron deficiency * history of acquired iron overload * need for revascularization, st-segment elevation myocardial infarction or non-st-segment elevation myocardial infarction during the past 3 months (at time of randomization) * women who are pregnant or of childbearing age and not using medically acceptable effective contraception

Keywords: heart failure iron deficiency anemia ferric carboxymaltose
impact of a community-based primary health care project on the inappropriate use of emergency medical system in bergamo

Conditions: Primary Health Care

Summary: the goal of this study is to reduce the inappropriate use of the emergency medical system in bergamo. the main question it aims to answer is: can a community-based primary health care project impact on the use of the emergency medical system in bergamo? monthly changes in urgent calls to the emergency medical system will be analysed.


Eligibility criteria:
inclusion criteria: * urgent emergency medical system call exclusion criteria: * non-urgent emergency medical system call
drug interaction study of gbt440 with caffeine, s-warfarin, omeprazole, and midazolam in healthy subjects

Conditions: Sickle Cell Disease

Summary: the purpose of this study to evaluate the effect of concomitant administration of gbt440 on caffeine (a cyp1a2 probe substrate), s warfarin (a cyp2c9 probe substrate), omeprazole (a cyp2c19 probe substrate), and midazolam (a cyp3a4 probe substrate) plasma concentrations.


Eligibility criteria:
inclusion criteria: * subject is a female of non-childbearing potential or male, who is healthy, nonsmoking, and 18 to 55 years old, inclusive, at screening * male subjects agree to use contraception * willing and able to give written informed consent exclusion criteria: * evidence or history of clinically significant metabolic, allergic, dermatological, hepatic, renal,hematological, pulmonary, cardiovascular, gastrointestinal, neurological, or psychiatric disorder * history of hypersensitivity or allergy to drugs, foods, or other substances * history or presence of abnormal electrocardiogram or hypertension * history of alcohol abuse, illicit drug use, significant mental illness, physical dependence to any opioid, or any history of drug abuse or addiction within 1 year of screening * participated in another clinical trial of an investigational drug within 30 days (or 5 half-lives of the investigational drug, whichever is longer) prior to screening

Keywords: anemia, sickle cell
impact of dexmedetomidine on the post-operative cognition dysfunction(pocd) in geriatric patients

Conditions: Postoperative Confusion; Delirium

Summary: post-operative cognition dysfunction (pocd) is a common complication after surgery, pocd can lead to a reduced ability and seriously affect the quality of life of patients, increase personal and social burden, pocd may also increase mortality.pocd can occur at any age, but the long-term, affect the daily lives of pocd in elderly patients over 60 years of age are more prone. age is a risk factor for advanced or long-term pocd. pocd determined by preoperative cognitive function and psychological scales postoperative assessment, the main recommendation of the agreed test methods include, rey auditory verbal test, the connection test, digit span test. in this study, preoperative mini-mental state examination (mmse) screening, comprehensive neurological function during hospitalization for memory, attention, executive function and exercise capacity test, and telephone follow-up after discharge scale revised (tics-m) test. few study showed that dexmedetomidine may improve cognitive function in young patients others show that dexmedetomidine did not reduce pocd incidence after 24 hours of surgery. these results conflict and it is necessary to carry out large-scale, multi-center, randomized, controlled clinical study to determine whether dexmedetomidine reduce the pocd incidence or not for elderly patients.


Eligibility criteria:
inclusion criteria: 1. written informed consent 2. selective surgery and general anesthesia patients(abdomen,orthopedics and urology surgery is preferred）； 3. age 65-90 yrs； 4. anesthesia society of american (asa) scale ii\~iii； 5. anticipated surgery time 2-6 hrs； - exclusion criteria: 1. dementia patients（mini-mental state examination\< 20） 2. factors existed that affect cognition assessment such as language,visual,and auditory dysfunction； 3. unstable metal status and mental disease； 4. the cognitive function examination in 3-6 months is not anticipated to be completed 5. ii-iii atrioventricular block； 6. heat rate \< 50 beats/minutes； 7. parkinson's disease； 8. may occur or have occurred the difficult airway or anticipated delayed extubation 9. sure or suspected abuse of analgesic and sedation drug； 10. allergic to the trial drug and other anesthesia drug contraindication； -

Keywords: dexmedetomidine
comparison of the effectiveness of single-dose methotrexate protocol with letrozole + single-dose methotrexate in the medical treatment of patients diagnosed with ectopic pregnancy

Conditions: Ectopic Pregnancy

Summary: the objective of the study is to compare the effectiveness of single-dose methotrexate and letrozole + single-dose methotrexate in treating ectopic pregnancy, focusing on treatment success, changes in ß-hcg levels, hemogram and biochemical markers, surgical intervention due to rupture, fertility preservation, and reduction of maternal morbidity, mortality, and healthcare costs. this is a prospective study conducted on 60 ectopic pregnancy patients at van yuzuncu yil university from june 2021 to september 2022. thirty patients received single-dose methotrexate, while the other thirty received letrozole + single-dose methotrexate. inclusion criteria were ß-hcg \<5000 miu/ml, ectopic mass \<3-4 cm, no persistent abdominal pain, no fetal cardiac activity, and no contraindications to the treatments. outcomes measured included treatment success, blood parameter changes, and the need for surgical intervention.


Eligibility criteria:
inclusion criteria: * patients diagnosed with ectopic pregnancy according to the diagnostic criteria * patients with β-hcg levels \<5000 miu/ml, * patients without serious or persistent abdominal pain * patients without fetal cardiac activity observed * ectopic mass size smaller than 3-4 cm * patients without contraindications for methotrexate and letrozole exclusion criteria: * ruptured ectopic pregnancies * hemodynamically unstable patients * patients with acute abdomen or intra-abdominal bleeding * patients with fetal cardiac activity * β-hcg levels below 500 miu/ml or above 5000 miu/ml * patients non-compliant with treatment * ectopic pregnancy size over 40 mm

Keywords: methotrexate letrozole